Epigenomics AG Product Pipeline Analysis

SUMMARY

Epigenomics AG Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Epigenomics AG's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

TABLE OF CONTENTS

1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Company Snapshot 8
2.1 Key Information 8
2.2 Company Overview 8
2.3 Financial Performance 8
2.4 Industry Outlook -- In Vitro Diagnostics 8
3 Business Description 9
3.1 Business Overview 9
3.2 Major Products and Services 9
3.2.1 Overview 9
4 Competitors 10
5 Key Employees 11
6 Key Employee Biographies 12
7 Company Statement 13
8 Locations And Subsidiaries 15
8.1 Head Office 15
8.2 Other Locations & Subsidiaries 15
9 Recent Developments 16
9.1 Strategy And Business Planning 16
9.1.1 Jan 14, 2008: Epigenomics Enters Into Strategic Cross-Licensing Agreement With DxS 16
9.1.2 Jan 14, 2008: Epigenomics Issues Technology Licenses To OncoMethylome 16
9.1.3 Sep 26, 2007: Epigenomics Signs Agreement With Abbott 17
9.1.4 May 09, 2007: Epigenomics Enters R&D Collaboration With Myriad 17
9.1.5 Apr 12, 2007: Epigenomics Forms Alliance With Clinical Data For DNA Methylation Services 17
9.2 Financial Announcements 18
9.2.1 Aug 05, 2008: Epigenomics Reports 1H 2008 Results 18
9.2.2 May 06, 2008: Epigenomics Reports Q1 2008 Results 20
9.2.3 Mar 31, 2008: Epigenomics Reports 2007 Results 22
9.2.4 Mar 13, 2008: Epigenomics To Declare 2007 Results 24
9.2.5 Oct 31, 2007: Epigenomics Declares Q3 2007 Results 24
9.2.6 Aug 02, 2007: Epigenomics Declares H1 2007 Results 25
9.2.7 May 03, 2007: Epigenomics Declares Q1 2007 Results 27
9.2.8 Mar 30, 2007: Epigenomics Declares 2006 Results 29
9.3 Research And Development 31
9.3.1 May 09, 2007: Epigenomics Enters R&D Collaboration With Myriad 31
9.4 Corporate Communications 31
9.4.1 Aug 05, 2008: Epigenomics Announces Management Changes 31
9.4.2 Jan 21, 2008: Epigenomics Appoints New Advisory Board Member 32
9.4.3 Jan 16, 2008: Epigenomics Appoints New CEO 32
9.5 Product News 33
9.5.1 Apr 21, 2008: Epigenomics AG Successfully Validates Optimized Blood-Based Colorectal Cancer Assay In Two Independent Clinical Studies 33
9.5.2 Apr 14, 2008: Epigenomics AG Presents Data on Novel Prostate Cancer Biomarkers at AACR 33
9.5.3 Feb 19, 2008: Epigenomics Licenses Septin 9 Colorectal Cancer Biomarker To Quest Diagnostics 34
9.6 Clinical Trials 34
9.6.1 Apr 21, 2008: Epigenomics AG Successfully Validates Optimized Blood-Based Colorectal Cancer Assay In Two Independent Clinical Studies 34
10 Epigenomics AG Pipeline Products 36
10.1 Epigenomics AG Product Pipeline Analysis 36
10.1.1 Epigenomics AG Pipeline Products By Equipment Type 36
10.1.2 Epigenomics AG Pipeline Products By Development Stage 37
10.1.3 Epigenomics AG Pipeline Products By Therapy Area 38
10.1.4 Epigenomics AG Pipeline Products By Clinical Trials 38
10.1.5 Epigenomics AG Pipeline Products By News Summary 39
10.2 Colorectal cancer screening test 39
10.2.1 Product Description 40
10.2.2 Product Status 40
10.2.3 Clinical Trials 40
10.2.4 Product Milestone 41
10.3 Prostate Cancer Screening Test 42
10.3.1 Product Description 42
10.3.2 Product Status 42
10.3.3 Product Milestone 42
10.4 Lung Cancer Screening Test 43
10.4.1 Product Description 43
10.4.2 Product Status 43
10.4.3 Clinical Trials 43
10.4.4 Product Milestone 44
11 Appendix 45
11.1 Methodology 45
11.1.1 Coverage 45
11.1.2 Secondary Research 46
11.1.3 Primary Research 46
11.1.4 Expert Panel Validation 47
11.2 Contact Us 47
11.3 About Global Markets Direct 47
11.4 Disclaimer 47

1.1 List of Tables
Table 1: Epigenomics AG,Key Facts 8
Table 2: Epigenomics AG, Key Employees, 11
Table 3: Epigenomics AG, Other Locations 15
Table 4: Epigenomics AG, Subsidiaries 15
Table 5: Epigenomics AG Pipeline Products by Equipment Type 36
Table 6: Epigenomics AG Pipeline Products By Development Stage 37
Table 7: Epigenomics AG Pipeline Products By Therapy Area 38
Table 8: Epigenomics AG Pipeline Products By Clinical Trials 38
Table 9: Epigenomics AG Pipeline Products By News Summaries 39

1.2 List of Figures
Figure 1: Epigenomics AG Pipeline Products By Development Stage 37
Figure 2: Epigenomics AG Pipeline Products By News Summary 39
Figure 3: Global Markets Direct Methodology 45